Literature DB >> 9806100

Are there potential non-lipid-lowering uses of statins?

D C Wheeler1.   

Abstract

Recent clinical trials have demonstrated beyond doubt that statins are effective in the prevention of acute coronary events. Critical analysis of these studies suggests that the benefits of statin therapy cannot be fully explained on the basis of reductions in plasma cholesterol levels. Accumulating knowledge of the actions of these drugs shows that they may prevent several processes that eventually lead to plaque rupture and the development of occlusive thrombosis, the basis of acute coronary events. Hence, statins may correct endothelial dysfunction (thus protecting against ischaemic injury), stabilise existing plaques and modify the coagulation pathway, thereby reducing the likelihood of a sudden vascular event. At a cellular level, these drugs inhibit the synthesis not just of cholesterol, but of other compounds important in cell proliferation. Antiproliferative effects have been demonstrated in vitro and may broaden the applications of statins to the treatment of noncardiovascular diseases. Finally, preliminary clinical studies indicate that as a result of immunosuppressive actions, statins may reduce the incidence of rejection following organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806100     DOI: 10.2165/00003495-199856040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  47 in total

Review 1.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2.

Authors:  J L Cutts; A D Bankhurst
Journal:  J Cell Physiol       Date:  1990-11       Impact factor: 6.384

4.  Effect of simvastatin on ejection fraction in cardiac transplant recipients.

Authors:  G H Jenkins; L A Grieve; M H Yacoub; D R Singer
Journal:  Am J Cardiol       Date:  1996-12-15       Impact factor: 2.778

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies.

Authors:  M Aviram; G Dankner; U Cogan; E Hochgraf; J G Brook
Journal:  Metabolism       Date:  1992-03       Impact factor: 8.694

7.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

Authors:  R P Byington; J W Jukema; J T Salonen; B Pitt; A V Bruschke; H Hoen; C D Furberg; G B Mancini
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

8.  Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH).

Authors:  H Buchwald; C T Campos; J R Boen; P A Nguyen; S E Williams
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

9.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

Authors:  S Katznelson; A H Wilkinson; J A Kobashigawa; X M Wang; D Chia; M Ozawa; H P Zhong; M Hirata; A H Cohen; P I Teraski
Journal:  Transplantation       Date:  1996-05-27       Impact factor: 4.939

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  12 in total

Review 1.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Are cardiovascular diseases a subspeciality of clinical immunology?

Authors:  Pier Luigi Meroni; Piersandro Riboldi
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

3.  Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Denis Talbot; Joseph A Chris Delaney; Veit Sandfort; David M Herrington; Robyn L McClelland
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-06       Impact factor: 2.890

Review 4.  Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?

Authors:  Pier Luigi Meroni; Cristina Luzzana; Donatella Ventura
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

5.  Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting.

Authors:  Young-Cheoul Doo; Sang-Jin Han; Sung-Woo Han; Woo-Jung Park; Seung-Hyuk Choi; Goo-Yeong Cho; Kyung-Soon Hong; Kyoo-Rok Han; Nam-Ho Lee; Dong-Jin Oh; Kyu-Hyung Ryu; Chong-Yun Rim; Kwang-Hahk Lee; Yung Lee
Journal:  Clin Cardiol       Date:  2005-02       Impact factor: 2.882

Review 6.  Immune mechanisms and novel pharmacological therapies of acute kidney injury.

Authors:  Amandeep Bajwa; Gilbert R Kinsey; Mark D Okusa
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

7.  Effects of d-003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy volunteers.

Authors:  Gladys Castaño; Roberto Menéndez; Rosa Más; Nuris Ledón; Julio Fernández; Johany Pérez; Rosa M González; Magnolia Lezcay
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 8.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

Review 9.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Dyslipidemia.

Authors:  Adam M. Cohen; Daniel J. Rader
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.